IXC.AU · Invex Therapeutics Ltd

-

Please sign in to comment on IXC.AU

1 Comment

Admin

4 years, 1 month ago

Invex Therapeutics Ltd is currently in a long term downtrend where the price is trading 17.9% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Invex Therapeutics Ltd's total revenue rose by 24.7% to $115K since the same quarter in the previous year.

Its net income has increased by 4.9% to $-1M since the same quarter in the previous year.

Finally, its free cash flow fell by 69.6% to $-406K since the same quarter in the previous year.

Based on the above factors, Invex Therapeutics Ltd gets an overall score of 3/5.

Exchange	AU
Sector	Healthcare
Industry	Biotechnology
CurrencyCode	AUD
ISIN	AU0000048621

Market Cap	6M
PE Ratio	None
Target Price	None
Beta	0.22
Dividend Yield	None

ABOUT

Invex Therapeutics Ltd

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

IXC.AU · Invex Therapeutics Ltd

-

Invex Therapeutics Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Invex Therapeutics Ltd using a moving average strategy